Courtesy of Benzinga.
Amylin (NASDAQ: AMLN) is considering a sale of the company, according to sources cited by Reuters. Amylin is attempting to fight off a law suit by investor Carl Icahn. The company recently rejected a $3.5 billion takeover offer from Bristol-Myers Squibb (NYSE: BMY).
For more Benzinga, visit Benzinga Professional Service, Value Investor, and Stocks Under $5.